The CLOSURE-AF trial compared left atrial appendage closure (LAAC) using percutaneous catheter devices with medical therapy in patients with nonvalvular atrial fibrillation, CHA2DS2-VASc score ≥2, and high bleeding risk (HAS-BLED ≥3, prior major bleeding, or chronic kidney disease with eGFR 15–29 mL/min/1.73 m²).[1] The average age of the patients was 79.5 years in the LAAC group and 78.4 years in the drug therapy group, 38.6% were women.[1] Patients in the LAAC group received individualized antithrombotic therapy after the procedure, usually dual antiplatelet therapy for 3 months.[1] The primary composite endpoint (16.83 vs. 13.27 events per 100 patient-years) showed noninferiority of LAAC to medical therapy (HR 1.28; 95% CI 1.01–1.62; P for noninferiority = 0.44).[1] Cardiovascular or unclear death reached 9.47 vs. 7.45 events per 100 patient-years (HR 1.25).[1] Total mortality was 14.83 vs. 13.49 events per 100 patient-years (HR 1.12).[1]